HORSHAM, PA, June 2, 2014 – Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer (M0-CRPC) at high risk of developing metastatic disease.
Janssen Biotech, Inc. today announced the results from this study, which also found significant reductions in testosterone levels, a key secondary endpoint.
IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC) | Johnson & Johnson
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.